Miguel Wilken

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Current treatment practice of Guillain-Barré syndrome

Christine Verboon, Alex Y. Doets, Giuliana Galassi et al. · Neurology · 2019 · 88 citations · Full text

Life Sciences, Internal Medicine, Neurology +12

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Differences between acute‐onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients

Lucas Alessandro, José Manuel Pastor Rueda, Miguel Wilken et al. · Journal of the Peripheral Nervous System · 2018 · 42 citations

Medicine, Neurology, Neuroscience +14